Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial

PPC heparin use was associated with greater heparin and protamine dose requirements than Hepalean. These findings indicate that heparin preparations are not interchangeable and suggest that a direct comparison of the potency with the brand in use is needed if a change is made to ensure that the agents exert similar anticoagulant effects in vivo.